Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Inclusion Criteria: * Males or females with advanced, recurrent or metastatic cancer, refractory to standard therapy; * Age ≥18 years; * Signed informed consent form and ability to understand the study procedures. Exclusion Criteria: * Concomitant anticancer therapy, including radiation; * Current or previous (within 30 days of first study dosing) treatment with another investigational drug or participation in another clinical study; * Chronic daily treatment with aspirin (\>325 mg/day) or clopidogrel (\>75 mg/day); * Chronic daily treatment with corticosteroids, with the exception of inhaled steroids; * Inadequate bone marrow function; * Inadequate liver function; * Inadequate renal function; * Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) \>1.5 or an activated partial thromboplastin time (aPTT) \>1.5 x ULN within 7 days prior to first study treatment; * Patients with lymphomas; * Evidence of spinal cord compression or brain metastases; * Other malignancy diagnosed within the previous 5 years; * Pregnant or lactating females.; * All patients who do not use a highly effective method of birth control; * Major surgical procedure (including open biopsy) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment; * Minor surgical procedures, within 24 hours prior to the first study treatment; * History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding; * Uncontrolled hypertension or clinically significant (i.e. active) cardiovascular disease; * History of abdominal fistula, grade 4 bowel obstruction or gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment; * Lung carcinoma of squamous cell histology or any histology in close proximity to a major vessel; * Serious non-healing wound, peptic ulcer or bone fracture; * Known hypersensitivity to the study medication or any of its excipients; * Evidence of any other medical conditions that may interfere with the planned treatment, affect patient compliance or place the patient at high risk of treatment-related complications; * Previous enrollment in this study; * Known hepatitis B or C or HIV infection; * Employees of the sponsor or patients who are employees or relatives of the investigator.